Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies.

BACKGROUND There are numerous potential sources of interference in immunoassays. Our aim was to identify the blood component that causes negative interference in cardiac troponin I (cTnI) immunoassays based on antibodies against the central part of cTnI. METHODS We isolated an interfering factor (IF) from a sample with low recovery of added cTnI, using several consecutive purification steps: caprylic acid precipitation, ammonium sulfate precipitation, and purification on Cibacron Blue gel and protein G columns. Purified IF was identified by gel electrophoresis and mass spectrometric analysis of protein bands. For the direct detection of human antibodies to cardiac troponin in serum samples, we developed immunoassays using three different anti-human immunoglobulin antibodies and measured troponin antibodies in samples with low and normal cTnI recovery. RESULTS Treatment with caprylic acid did not precipitate IF, but IF precipitated at 40% ammonium sulfate saturation. IF bound to a Cibacron Blue gel column, from which it was eluted with a linear salt gradient; it also bound to protein G. Gel electrophoresis of purified IF showed two major bands with molecular masses corresponding to the heavy (approximately 50 kDa) and light chains (approximately 25 kDa) of immunoglobulin, and their identities were confirmed by mass spectrometry. The presence of troponin-specific autoantibodies was confirmed in samples with low recoveries of cTnI by three different immunoassays. The median signals were significantly higher in 10 samples with low recovery than in 10 samples with normal recovery of cTnI (P < or = 0.007). CONCLUSIONS Circulating autoantibodies to cTnI or other proteins of the troponin complex can be a source of negative interference in cTnI immunoassays.

[1]  P. Porela,et al.  Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. , 2005, Clinical chemistry.

[2]  Mauro Panteghini,et al.  Innotrac aio! Second-generation cardiac troponin I assay: imprecision profile and other key characteristics for clinical use. , 2004, Clinical chemistry.

[3]  Kim Pettersson,et al.  An interfering component in cardiac troponin I immunoassays-Its nature and inhibiting effect on the binding of antibodies against different epitopes. , 2004, Clinical biochemistry.

[4]  H. Alfthan,et al.  Negative interference in cardiac troponin I immunoassays from a frequently occurring serum and plasma component. , 2003, Clinical chemistry.

[5]  Kim Pettersson,et al.  A europium chelate for quantitative point-of-care immunoassays using direct surface measurement. , 2003, Analytical chemistry.

[6]  S. S. Levinson,et al.  Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[7]  J. Barth,et al.  Interference in immunoassay is an underestimated problem , 2002, Annals of clinical biochemistry.

[8]  E. Braunwald,et al.  Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.

[9]  A. Wu,et al.  Quality Specifications for Cardiac Troponin Assays , 2001, Clinical chemistry and laboratory medicine.

[10]  K. Thygesen,et al.  Erratum: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (Journal of the American College of Cardiology (2000) 36 (959-969)) , 2001 .

[11]  A. Dasgupta,et al.  Negative interference of bilirubin and hemoglobin in the MEIA troponin I assay but not in the MEIA CK‐MB assay , 2001, Journal of clinical laboratory analysis.

[12]  B. Bluestein,et al.  Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. , 2000, Circulation.

[13]  K Irjala,et al.  Time-resolved fluorometry (TRF)-based immunoassay concept for rapid and quantitative determination of biochemical myocardial infarction markers from whole blood, serum and plasma. , 2000, Luminescence : the journal of biological and chemical luminescence.

[14]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[15]  M. Panteghini.  Present issues in the determination of troponins and other markers of cardiac damage. , 2000, Clinical biochemistry.

[16]  S. Hill,et al.  Effect of rheumatoid factor on cardiac troponin I measurement using two commercial measurement systems. , 2000, Clinical chemistry.

[17]  M. Plebani,et al.  Effect of Rheumatoid Factor on Cardiac Troponin I Measurement Using Two Commercial Measurement Systems , 2000 .

[18]  A. Dasgupta,et al.  False-positive troponin I in the MEIA due to the presence of rheumatoid factors in serum. Elimination of this interference by using a polyclonal antisera against rheumatoid factors. , 1999, American journal of clinical pathology.

[19]  C. Selby,et al.  Interference in Immunoassay , 1999, Annals of clinical biochemistry.

[20]  N. Gusev,et al.  Troponin: structure, properties, and mechanism of functioning. , 1999, Biochemistry. Biokhimiia.

[21]  J. Krahn,et al.  High percentage of false positive cardiac troponin I results in patients with rheumatoid factor. , 1999, Clinical biochemistry.

[22]  W. Gibler,et al.  National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. , 1999, Clinical chemistry.

[23]  L J Kricka,et al.  Human anti-animal antibody interferences in immunological assays. , 1999, Clinical chemistry.

[24]  A. Katrukha,et al.  Biochemical Factors Influencing Measurement of Cardiac Troponin I in Serum , 1999, Clinical chemistry and laboratory medicine.

[25]  F. Apple,et al.  Clinical and analytical standardization issues confronting cardiac troponin I. , 1999, Clinical chemistry.

[26]  L. Voipio‐Pulkki,et al.  Degradation of cardiac troponin I: implication for reliable immunodetection. , 1998, Clinical chemistry.

[27]  N. Rifai,et al.  False increase of cardiac troponin I with heterophilic antibodies. , 1998, Clinical chemistry.

[28]  R. Solaro,et al.  Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. , 1998, Circulation research.

[29]  A. Bereznikova,et al.  Epitope mapping of anti‐troponin I monoclonal antibodies , 1998, Biochemistry and molecular biology international.

[30]  Christian Scheler,et al.  Peptide mass fingerprint sequence coverage from differently stained proteins on two‐dimensional electrophoresis patterns by matrix assisted laser desorption/ionization‐mass spectrometry (MALDI‐MS) , 1998, Electrophoresis.

[31]  D. Laune,et al.  Human cardiac troponin I: precise identification of antigenic epitopes and prediction of secondary structure. , 1998, Clinical chemistry.

[32]  C. Granier,et al.  Antigenic Definition of Cardiac Troponin I , 1998, Clinical chemistry and laboratory medicine.

[33]  K. Pulkki,et al.  Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. , 1997, Clinical chemistry.

[34]  K. O'Connell,et al.  Identification of mouse liver proteins on two‐dimensional electrophoresis gels by matrix‐assisted laser desorption/ionization mass spectrometry of in situ enzymatic digests , 1997, Electrophoresis.

[35]  J. Bohner,et al.  False-negative immunoassay results for cardiac troponin I probably due to circulating troponin I autoantibodies. , 1996, Clinical chemistry.

[36]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[37]  S. S. Levinson,et al.  7 – INTERFERENCES IN IMMUNOASSAYS , 1996 .

[38]  A. Campbell.  5 – PRODUCTION AND PURIFICATION OF ANTIBODIES , 1996 .

[39]  B. Beatty,et al.  Eliminating interference from heterophilic antibodies in a two-site immunoassay for creatine kinase MB by using F(ab')2 conjugate and polyclonal mouse IgG. , 1992, Clinical chemistry.

[40]  F. Dammacco,et al.  Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. , 1990, Journal of immunological methods.

[41]  M. McKinney,et al.  A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. , 1987, Journal of immunological methods.

[42]  R. Thompson,et al.  Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects--incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme. , 1986, Clinical chemistry.

[43]  G. Burdick,et al.  Purification of DNA antibodies using cibacron blue F3GA affinity chromatography. , 1983, Journal of immunological methods.

[44]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[45]  D. Seligson,et al.  Clinical Chemistry , 1965, Bulletin de la Societe de chimie biologique.